Hamaya R, et al. - In view of the strong predictive value of baseline cardiac troponin for major adverse cardiac events (MACE) and that the high sensitive assay can provide risk stratification under the 99th percentile values, researchers investigated the impact of percutaneous coronary intervention (PCI) on baseline high-sensitivity cardiac troponin-I (hs-cTnI) levels and the association with MACE incidence. They measured baseline hs-cTnI levels before PCI, for two times (the average: pre-PCI hs-cTnI) and 10 months after PCI (post-PCI remote hs-cTnI) in 401 patients with stable coronary artery disease who were indicated for PCI. Based on the pre-PCI values, they assessed hs-cTnI day-to-day variability and divided patients into three groups (increase/no change/decrease group) according to the extent of hs-cTnI change (post-PCI remote hs-cTnI minus pre-PCI hs-cTnI) considering the day-to-day variability. Pre-PCI hs-cTnI, hs-cTnI variability, the presence of dyslipidemia, multivessel disease, and lesions with chronic total occlusion or low quantitative flow ratio significantly predicted Hs-cTnI change following PCI. A certain subset of patients could display lower hs-cTnI levels in relation to PCI. In this patient subset, the prognostic benefit might be expected by the intervention.